AUTHORS
Lisett Contreras, PhD, Juan Martìn Barajas, PhD2, Masayuki Umeda, MD, PhD3, Josi Lott, BS4, Emily Xiong5, Chandra Rolle6, Haley Writt7, Tamara Westover, BS8, Mike P. Walsh9, Wojciech Rosikiewicz, PhD10, Hasan Reza11, Laura Janke12, Jing Ma, PhD13, Jeffery M. Klco, Member; Director, Division of Hematopathology and Molecular Pathology14
AFFILIATIONS
1 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
6 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
7 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
8 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
9 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
11 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
12 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
13 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
14 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
ABSTRACT
UBTF-tandem duplications (TDs) represent a subtype-defining alteration in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), most common in adolescents and young adults, that are associated with overall inferior patient outcomes. These alterations are somatic and heterozygous tandem duplications within exon 13 of the UBTF gene. Expression of UBTF-TD in human cord blood CD34+ (cbCD34) cells is sufficient to promote clonogenic activity, sustain proliferation, and induce transcriptional changes similar to those observed in patient samples. However, studies investigating the in vivo mechanisms by which UBTF-TDs drive disease in a physiological context remain poorly understood.
To address this, we explored UBTF-TD pathogenesis using in vivo murine models. UBTF-TD murine models were generated using two approaches: transplantation of retrovirally transduced UBTF-TD hematopoietic stem and progenitor cells (HSPCs) and a conditional knock-in mouse model. Retroviral expression of UBTF-TD in mouse HSPCs conferred enhanced self-renewal potential, and transplantation of these cells was sufficient to induce a myeloid neoplasm characterized by CD11b and Gr-1-positive cells in the bone marrow and spleen. To model physiological Ubtf-TD expression, we generated the conditional knock-in mouse model Ubtf-TD84, in which Ubtf-TD is expressed from the endogenous Ubtf locus following recombination by Cre recombinase driven by the pan-hematopoietic Vav promoter. Colony-forming unit (CFU) assays revealed that HSPCs from Ubtf-TD84 mice exhibit increased self-renewal potential compared to wild-type controls. Multiparameter flow cytometry revealed an expansion of granulocyte-monocyte progenitor (GMP; P < 0.05) and multipotent progenitor (MPP3, P < 0.0001) populations in Ubtf-TD84 mice in vivo as early as 15 weeks of age, which was further supported by single-cell RNA sequencing (scRNA-seq) demonstrating an enrichment of myeloid progenitor populations. These early hematopoietic alterations led to a fully penetrant, and serially transplantable, leukemia in Ubtf-TD84 mice with a latency ranging from 130-429 days. Leukemic mice developed leukocytosis, anemia, and splenomegaly with prominent CD11b and Gr-1 positive myeloid populations in the bone marrow and spleen, as demonstrated by immunohistochemistry and flow cytometry. High-parameter flow cytometry of leukemic Ubtf-TD84 bone marrow demonstrated marked myeloid skewing, including an increase of GMPs, which were altered early in disease development, and an expanded monocyte population. Profiling of these tissues by RNA-sequencing (RNA-Seq) identified dysregulation of Hox cluster genes, consistent with transcriptional programs observed in human UBTF-TD AML. At the chromatin level, CUT&RUN and ATAC-sequencing revealed increased H3K27ac and chromatin accessibility at key loci implicated in UBTF-TD pathogenesis, including the Hoxa and Hoxb clusters.
Collectively, these studies demonstrate that Ubtf-TD expression is sufficient to drive leukemia in vivo. Using a conditional knock-in Ubtf-TD84 mouse model, we gained insight into the impact of physiological Ubtf-TD expression on hematopoietic development, identifying early alterations in myeloid progenitor populations and a monocyte expansion. We also demonstrated that Ubtf-TD expression induces transcriptional and chromatin changes to induce a leukemic program. The Ubtf-TD conditional knock-in model recapitulates key features of UBTF-TD AML and provides a valuable platform for investigating leukemia initiation, progression, and therapeutic vulnerabilities.
DISCLOSURES
Lisett Contreras, PhD: No relevant conflicts of interest to declare.